Objective: The study is aimed at assessment of time trend for substance use disorder and psychiatric disorders among patients seeking treatment from a dual diagnosis clinic of a tertiary care substance use disorder treatment centre in India. Methods: The study is based on chart review of the patients seeking treatment from the Dual Diagnosis Clinic of a tertiary care substance use disorder treatment centre. The records of the patients seeking treatment over a six-year period (2009-2014) were reviewed. Information was collected on sociodemographic variables, substance use disorder and co-occurring psychiatric disorder. Results: A total of 289 patients sought treatment from the dual diagnosis clinic of the centre. Majority were male (97.2%). Primary drugs of abuse were nicotine (74.4%), alcohol (49.5%), cannabis (38.4%), and opioids (28.7%). Most common co-occurring psychiatric disorders were psychiatric disorders, including schizophrenia (45.0%), Major depressive disorder (24.9%), Bipolar disorder (18.3%), anxiety disorder (4.5%) and OCD (2.4%). Most patients with psychotic disorders and depressive disorders had co-occurring alcohol dependence. Most patients with bipolar disorder had co-occurring cannabis dependence. There was a marginally significant increase in proportion of subjects with cannabis dependence (PTrend= .07). There was no significant time trend for various co-occurring psychiatric disorders. Conclusions: The findings of the current study suggest that there has been a marginally significant increase in proportion of subjects with cannabis dependence over the six study years. However, the proportion of co-occurring psychiatric disorders was stable across these years. The findings of the current study suggest that the centre should be prepared to cater to an increasing proportion of patients with cannabis dependence and possibly co-occurring psychotic disorders in the coming years. ASEAN Journal of Psychiatry, Vol. 17 (2): July – December 2016: XX XX.

Nicotine, the primary psychoactive component of tobacco products, produces diverse neurophysiological, motivational, and behavioral effects through several brain regions and neurochemical pathways. Various neurotransmitter systems have been explored to understand the mechanisms behind nicotine tolerance, dependence, and withdrawal. Recent evidence suggests that glutamate neurotransmission has an important role in this phenomenon. The aim of the present review is to discuss preclinical findings concerning the role of N-methyl-D-aspartate (NMDA) receptor neurotransmission in mediating the behavioral effects of nicotine, tolerance, sensitization, dependence, and withdrawal. Based on preclinical findings, it is hypothesized that NMDA receptors mediate the common adaptive processes that are involved in the development, maintenance, and expression of nicotine addiction. Modulation of glutamatergic neurotransmission with NMDA receptor antagonists may prove to be useful in alleviating the symptoms of nicotine abstinence and facilitate tobacco-smoking cessation.
Animals ; Dizocilpine Maleate/pharmacology ; Drug Tolerance ; Excitatory Amino Acid Antagonists/*pharmacology ; Humans ; Nicotine/*administration & dosage ; Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors/physiology ; Substance Withdrawal Syndrome/physiopathology/prevention & control ; Tobacco Use Disorder/physiopathology/*prevention & control